Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Introduction
• Diagnosis and treatment

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing
• Market size and forecast

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY THERAPY
• Segmentation by therapy
• Comparison by therapy
• Global hormone-based therapy market
• Global others market
• Market opportunity by therapy

PART 10: MARKET SEGMENTATION BY GENDER
• Segmentation by gender
• Global female infertility drugs market
• Global male infertility drugs market

PART 11: CUSTOMER LANDSCAPE

PART 12: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Infertility drugs market in Americas
• Infertility drugs market in EMEA
• Infertility drugs market in APAC
• Market opportunity

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 15: MARKET TRENDS
• Raising awareness regarding infertility in couples
• Growing online retail sales of drugs

PART 16: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 17: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• Ferring
• Merck
• Novartis

PART 18: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Definition of infertility in different genders
Exhibit 02: Fertility rates, 2015
Exhibit 03: Parent market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition: Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global infertility drugs market 2017-2022 ($ millions)
Exhibit 10: Major factors affecting the global infertility drugs market 2017
Exhibit 11: Global infertility drugs market: Year-over-year (YoY) growth 2018-2022 (%)
Exhibit 12: Five forces analysis 2017
Exhibit 13: Five forces analysis 2022
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition: Five forces 2017
Exhibit 20: Pipeline analysis by development phase
Exhibit 21: Key clinical trials
Exhibit 22: Segmentation of global infertility drugs market by therapy 2017-2022 (%)
Exhibit 23: Comparison by therapy
Exhibit 24: Global hormone-based therapy market 2017-2022 ($ millions)
Exhibit 25: Hormonal therapy for infertility
Exhibit 26: Global hormone-based therapy market: Y0Y growth 2018-2022 (%)
Exhibit 27: Global others market 2017-2022 ($ millions)
Exhibit 28: Global others market: YoY growth 2018-2022 (%)
Exhibit 29: Market opportunity by therapy
Exhibit 30: Segmentation of global infertility drugs market by gender 2017
Exhibit 31: Customer landscape
Exhibit 32: Global infertility drugs market share by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Infertility drugs market in Americas 2017-2022 ($ millions)
Exhibit 35: Infertility drugs market in Americas: YoY growth 2018-2022 (%)
Exhibit 36: Fertility rate in top three countries in Americas 1960-2015
Exhibit 37: Top three countries in Americas
Exhibit 38: Infertility drugs market in EMEA 2017-2022 ($ millions)
Exhibit 39: Infertility drugs market in EMEA: YoY growth 2018-2022 (%)
Exhibit 40: Fertility rate in top three countries in EMEA 1960-2015
Exhibit 41: Top three countries in EMEA
Exhibit 42: Infertility drugs market in APAC 2017-2022 ($ millions)
Exhibit 43: Infertility drugs market in APAC: YoY growth 2018-2022 (%)
Exhibit 44: Fertility rate in top three countries in APAC 1960-2015
Exhibit 45: Top three countries in APAC
Exhibit 46: Market opportunity
Exhibit 47: Pregnancy complications in diabetic women after embryo implantation
Exhibit 48: Diabetes effect on men fertility
Exhibit 49: Global fertility rate
Exhibit 50: Demographic and economic snapshot of India and China
Exhibit 51: Non-therapeutic mode of infertility treatment
Exhibit 52: Side effects of medications used in infertility treatment
Exhibit 53: Vendor landscape
Exhibit 54: Landscape disruption
Exhibit 55: Vendors covered
Exhibit 56: Vendor classification
Exhibit 57: Market positioning of vendors
Exhibit 58: Bayer: Vendor overview
Exhibit 59: Bayer: Business segments
Exhibit 60: Bayer: Organizational developments
Exhibit 61: Bayer: Geographic focus
Exhibit 62: Bayer: Segment focus
Exhibit 63: Bayer: Key offerings
Exhibit 64: Ferring: Vendor overview
Exhibit 65: Ferring: Business segments
Exhibit 66: Ferring: Organizational developments
Exhibit 67: Ferring: Geographic focus
Exhibit 68: Ferring: Segment focus
Exhibit 69: Ferring: Key offerings
Exhibit 70: Merck: Vendor overview
Exhibit 71: Merck: Business segments
Exhibit 72: Merck: Organizational developments
Exhibit 73: Merck: Geographic focus
Exhibit 74: Merck: Segment focus
Exhibit 75: Merck: Key offerings
Exhibit 76: Novartis: Vendor overview
Exhibit 77: Novartis: Business segments
Exhibit 78: Novartis: Organizational developments
Exhibit 79: Novartis: Geographic focus
Exhibit 80: Novartis: Segment focus
Exhibit 81: Novartis: Key offerings